| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10148273 | Lung Cancer | 2018 | 7 Pages |
Abstract
This is the first prospective study designed to evaluate the efficacy of a specific chemotherapeutic regimen as the primary endpoint in patients with advanced NSCLC with ILD. The combination of S-1 with CBDCA may be a treatment option for advanced NSCLC patients with ILD (The clinical trial registration number: UMIN000011046).
Keywords
NSIPRB-ILDrespiratory bronchiolitis-interstitial lung diseaseIIPS-1CBDCAMPFSDCRUIPEORTC QLQ-C30HRCTECoGDIPQOLLIPVASMSTORRIPFQuality of lifeBSAPFsILDprogression-free survivaloverall survivalInterstitial lung diseasestable diseaseprogressive diseaseanalysis of varianceANOVAacute exacerbationhigh-resolution computed tomographycomputed tomographyRECISTmedian survival timeNon-small-cell lung cancerNSCLCNon-small cell lung cancerbody surface areaeastern cooperative oncology groupconfidence intervalidiopathic pulmonary fibrosisResponse Evaluation Criteria in Solid Tumorsvisual analogue scaleoverall response rateDisease control ratePerformance statusPartial responsecomplete responseLymphoid interstitial pneumonianon-specific interstitial pneumoniaIdiopathic interstitial pneumoniaUsual interstitial pneumoniaDesquamative interstitial pneumoniaCarboplatin
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Masaki Hanibuchi, Soji Kakiuchi, Shinji Atagi, Fumitaka Ogushi, Eiji Shimizu, Takashi Haku, Yuko Toyoda, Masahiko Azuma, Mayo Kondo, Hiroshi Kawano, Kenji Otsuka, Satoshi Sakaguchi, Hiroshi Nokihara, Hisatsugu Goto, Yasuhiko Nishioka,